BioCentury
ARTICLE | Finance

Rempex remix

How track record of anti-infectives start-up Qpex’s team attracted NEA-led syndicate

October 26, 2018 3:56 PM UTC

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio.

The start-up’s management team includes former executives from Medicine Co.’s infectious disease unit, who came on board when that company acquired Rempex in 2013 for $140 million up front and up to $334 million in milestones. ...